SANOFI US SERVICES INC.

Organization · NJ
Hires government relations

pharmaceutical manufacturer

Who they hire

2024 · 3 filings · Budget/Appropriations, Copyright/Patent/Trademark, Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Trade (domestic/foreign)
$██,███ / qtrUnlock

What they lobby on

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
Copyright/Patent/Trademark · 2024 Q3
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; CMMI Proposed Accelerated Approval Payment Policy; CMMI Medicaid Proposed Rebate Rule.
Medicare/Medicaid · 2024 Q3
Issues related to appropriations, federal health programs, prescription drugs, and Type One Diabetes (T1D); H.R.9029/S.4942, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; H.R.9027/S.4690, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025.
Budget/Appropriations · 2024 Q3
Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, VICP Program, and insulin price cap; Type One Diabetes (T1D) and military healthcare; Educational discussions around Vaccine Injury Compensation Program; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Health Issues · 2024 Q3
Issues related to pharmaceutical IP and supply chain.
Trade (domestic/foreign) · 2024 Q3